

**DEVELOPMENT OF A MULTIPLEX REAL-TIME
PCR ASSAY FOR DETECTION OF FUNGAL
PATHOGENS IN INVASIVE MYCOSES**

YASMIN KHAIRANI BT MUHAMMAD ISMADI

UNIVERSITI SAINS MALAYSIA

2024

**DEVELOPMENT OF A MULTIPLEX REAL-TIME
PCR ASSAY FOR DETECTION OF FUNGAL
PATHOGENS IN INVASIVE MYCOSES**

by

YASMIN KHAIRANI BT MUHAMMAD ISMADI

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

August 2024

ACKNOWLEDGEMENT

In the name of Allah SWT, all praises for His blessings, guidance and mercy throughout this academic journey. First and foremost, I extend my deepest appreciation to my supervisor, Associate Professor Dr Azian Harun, for her invaluable guidance, support and encouragement throughout this research journey. I am truly grateful for her dedication and commitment to my academic development. I am also grateful to my co-supervisor, Associate Professor Dr Suharni Mohamad, for her insightful advice, encouragement, and contributions to this research.

My sincere thanks go to my parents, Muhammad Ismadi Husain and Tina Khairani Omar and my siblings, Yaasin Khairi, Yusuff Khairi, Yasarah Khairani and Yasirah Khairani for their unwavering love, encouragement, and support throughout this journey. Their sacrifices, understanding, and belief in my abilities have been a constant source of strength and motivation. I extend my appreciation to my colleagues and fellow researchers, Dr Nur Ain, Noreafifah, Nurul Iman, Rusna Meswari, Akmalina, Amalin, Anissa, Aulia, Syafiqah, Elmi, Naveed, Fatin, Dr Mai, Dr Ridhuan, and many more for their intellectual discussion and makes this journey joyful. I wish all the best and hope that our friendship lasts forever. I wish to honor the memory of my late friend, Roszaharah Yaacob. Her memory will forever remain a guiding light in my academic pursuits.

I would like to acknowledge all lecturers, lab technologists from the Department of Medical Microbiology & Parasitology whose expertise, assistance, and diligence have facilitated the smooth conduct of experiments and data analysis. My acknowledgement also to Long-term Research Grant Scheme from the Ministry of Higher Education Malaysia (203/PPSP/6171236) for the research funding support. Thank you.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS	iii
LIST OF TABLES	xi
LIST OF FIGURES	xiii
LIST OF SYMBOLS	xviii
LIST OF ABBREVIATIONS	xix
LIST OF APPENDICES	xxi
ABSTRAK	xxii
ABSTRACT	xxiv
CHAPTER ONE: INTRODUCTION	1
1.1 Problem statement.....	1
1.2 Rationale of the study	2
1.3 Research questions of the study	4
1.4 Objectives of the study	5
1.5 Flow chart of the study.....	6
CHAPTER TWO: LITERATURE REVIEW	7
2.1 Invasive fungal infections	7
2.2 Invasive aspergillosis	11
2.2.1 Burden of disease and epidemiology.....	13
2.2.2 Mycology and taxonomy	15
2.2.3 Virulence factors	18
2.2.4 Risk factors	19
2.2.5 Pathogenesis	20
2.2.6 Clinical manifestations	21
2.2.7 Management and treatment	25
2.3 Invasive candidiasis	27
2.3.1 Epidemiology	28
2.3.2 Nomenclature and taxonomy.....	30

2.3.3	Virulence factors	31
2.3.4	Risk factors	37
2.3.5	Pathogenesis	37
2.3.6	Clinical manifestations	40
2.4	Fungal cell wall	41
2.4.1	Structure of cell wall	42
	2.4.1(a) <i>Aspergillus fumigatus</i>	44
	2.4.1(b) <i>Candida albicans</i>	46
2.5	Laboratory diagnosis for fungal detection	48
2.5.1	Direct microscopy	48
2.5.2	Culture	49
2.5.3	Serological tests	50
2.5.4	Histopathology	51
2.5.5	Blood tests	53
	2.5.5(a) Antigen test (galactomannan)	53
	2.5.5(b) 1,3- β -D-glucan	55
2.5.6	Molecular detection	58
	2.5.6(a) Fluorescence in situ hybridization	58
	2.5.6(b) Matrix-Assisted Laser Desorption/Ionization Time-of- Flight Mass Spectrometry (MALDI-TOF MS)	59
	2.5.6(c) Polymerase chain reaction	61
	2.5.6(d) Next-generation sequencing	63
2.6	Challenges of validating diagnostic detection for invasive mycoses	64

**CHAPTER THREE: COMPARISON OF EIGHT FUNGAL DNA EXTRACTION
PROTOCOLS FOR FUNGAL DETECTION..... 66**

3.1	Introduction	66
3.1.1	Background of study	68
3.1.2	Objective of the study	70
3.2	Methodology	71
3.2.1	Preparation of buffers and stock solutions	71
	3.2.1(a) Lysis buffer	71
	3.2.1(b) Hydrochloric acid, 1 M	71
	3.2.1(c) Tris buffer, 10 mM	71

3.2.1(d)	Tris-HCl solution.....	72
3.2.1(e)	Tris-Borate-EDTA buffer, 0.5x	72
3.2.1(f)	Tris-EDTA buffer.....	72
3.2.2	Preparation of culture media	73
3.2.2(a)	Sabouraud dextrose agar.....	73
3.2.2(b)	Brain heart infusion agar	73
3.2.2(c)	Brain heart infusion broth.....	73
3.2.2(d)	Brain heart infusion broth with 20% glycerol	73
3.2.3	Fungal isolates	74
3.2.4	Fungal cultivation and maintenance.....	74
3.2.5	Inoculum preparation.....	75
3.2.5(a)	Neubauer chamber cell counting	76
3.2.5(b)	Plating method.....	78
3.2.6	Fungal DNA extraction	78
3.2.6(a)	DNeasy Blood & Tissue Kit (QIAGEN Inc., Germany)..	79
3.2.6(b)	Wizard® Genomic DNA Purification Kit (Promega Corporation, USA).....	80
3.2.6(c)	NucleoSpin® Blood QuickPure (Machery-Nagel, Germany).....	82
3.2.6(d)	Genomic DNA Mini Kit (GeneAid Biotech Ltd., Taiwan)	83
3.2.6(e)	Illustra Blood GenomicPrep Mini Spin Kit (GE Healthcare, UK).....	84
3.2.6(f)	Kaneka Easy DNA Extraction Kit version 2 (Kaneka Corporation, Japan).....	85
3.2.6(g)	Conventional phenol-chloroform method	86
3.2.7	Quantification and quality analysis of DNA	87
3.2.7(a)	DNA quantification	87
3.2.7(b)	ITS PCR.....	87
3.2.7(c)	Agarose gel electrophoresis.....	88
3.3	Results.....	90
3.3.1	Preparation of genomic DNA templates.....	90
3.3.2	Comparison of fungal DNA extraction	91
3.4	Discussion	96

CHAPTER FOUR: SPECIES-SPECIFIC PRIMERS DESIGN FOR THE	
DEVELOPMENT OF CONVENTIONAL MULTIPLEX PCR ASSAY..... 100	
4.1	Introduction 100
4.1.1	Background of study..... 101
4.1.2	Objective of the study..... 102
4.2	Methodology 103
4.2.1	Primers and probes design..... 103
4.2.2	Bioinformatics characterisation of primers and probes..... 105
4.2.3	Reconstitution of stock solutions of primers and probes..... 105
4.2.4	Preparation of primers and probes working solutions..... 107
4.2.5	Fungal and bacterial isolates 107
4.2.6	Sequencing PCR products 108
4.2.7	Inoculum suspensions for spiked blood preparation 108
4.2.8	Genomic DNA extraction..... 109
4.2.9	Whole blood DNA extraction..... 110
4.2.10	PCR amplification 110
4.2.11	Analytical specificity of the monoplex and multiplex PCR Assay 111
4.3	Results 113
4.3.1	Primers and probes design..... 113
4.3.2	Selection of target genes..... 113
4.3.3	Primer designs and characteristics..... 115
4.3.4	Probe designs and characteristics 117
4.3.5	Homo- and hetero-dimerization activities between the nucleotides 119
4.3.6	Amplicon sizes and characteristics..... 121
4.3.7	Development of conventional PCR for fungal identification..... 123
4.3.7(a)	Performance of monoplex PCR for identification of <i>A. fumigatus</i> 124
4.3.7(b)	Performance of monoplex PCR for identification of <i>A. terreus</i> 128
4.3.7(c)	Performance of monoplex PCR for identification of <i>C. albicans</i> 132
4.3.7(d)	Performance of monoplex PCR for identification of <i>C. glabrata</i> 137

4.3.8	Performance of multiplex PCR for identification of fungal identification	141
4.3.9	Evaluation of the analytical specificity of multiplex PCR.....	143
4.4	Discussion	145

CHAPTER FIVE: DEVELOPMENT OF REAL-TIME MULTIPLEX PCR ASSAY FOR RAPID SIMULTANEOUS INVASIVE MYCOSES IDENTIFICATION..... 149

5.1	Introduction	149
5.1.1	Background of the study.....	151
5.1.2	Objective of the study.....	153
5.2	Methodology	154
5.2.1	Genomic DNA extraction.....	154
5.2.2	Real-time PCR assay	154
5.2.3	Optimization of primers and probes concentrations.....	156
5.2.4	Analytical evaluation of the developed real-time PCR assay	156
5.2.4(a)	Analytical sensitivity evaluation.....	157
5.2.4(b)	Analytical specificity evaluation	158
5.2.5	Assay precisions	160
5.2.5(a)	Intra-assay evaluation	160
5.3	Results.....	162
5.3.1	Development of monoplex real-time PCR for fungal identification	162
5.3.1(a)	Performance of monoplex real-time PCR for identification of <i>A. fumigatus</i>	162
5.3.1(b)	Performance of monoplex real-time PCR for identification of <i>A. terreus</i>	163
5.3.1(c)	Performance of monoplex real-time PCR for identification of <i>C. albicans</i>	163
5.3.1(d)	Performance of monoplex real-time PCR for identification of <i>C. glabrata</i>	164
5.3.2	Preliminary specificity analysis of the developed monoplex real-time PCR.....	165
5.3.3	Optimization of primer concentrations of the developed monoplex real-time PCR.....	168

5.3.3(a)	Optimization of primer concentrations for monoplex <i>A. fumigatus</i> real-time PCR assay	168
5.3.3(b)	Optimization of primer concentrations for monoplex <i>A. terreus</i> real-time PCR assay	168
5.3.3(c)	Optimization of primer concentrations for monoplex <i>C. albicans</i> real-time PCR assay	169
5.3.3(d)	Optimization of primer concentrations for monoplex <i>C. glabrata</i> real-time PCR assay	169
5.3.4	Optimization of probe concentrations of the developed monoplex real-time PCR	173
5.3.4(a)	Optimization of probe concentrations for monoplex <i>A. fumigatus</i> real-time PCR assay	174
5.3.4(b)	Optimization of probe concentrations for monoplex <i>A. terreus</i> real-time PCR assay	174
5.3.4(c)	Optimization of probe concentrations for monoplex <i>C. albicans</i> real-time PCR assay	175
5.3.4(d)	Optimization of probe concentrations for monoplex <i>C. glabrata</i> real-time PCR assay	175
5.3.5	Development of monoplex real-time PCR for internal amplification control detection	179
5.3.5(a)	Performance of internal amplification control	179
5.3.5(b)	Preliminary specificity testing	179
5.3.5(c)	Optimization of internal amplification control template concentrations	181
5.3.5(d)	Efficiency, linearity, and limit of detection of IAC monoplex real-time PCR assay	183
5.3.6	Development of multiplex real-time PCR for fungal identification with incorporation of internal amplification control	185
5.3.6(a)	Performance of multiplex real-time PCR assay	185
5.3.6(b)	Linearity and efficiency of monoplex versus multiplex real-time PCR assay	188
5.3.6(c)	Analytical sensitivity of multiplex real-time PCR assay	193
5.3.6(d)	Analytical specificity of multiplex real-time PCR assay	194
5.3.6(e)	Intra-assay evaluation	196

5.4	Discussion	197
CHAPTER SIX: PERFORMANCE EVALUATION OF A MULTIPLEX REAL-TIME PCR ASSAY FOR DETECTION OF FUNGAL PATHOGENS		
		202
6.1	Introduction	202
6.1.1	Background of the study.....	203
6.1.2	Objective of the study.....	205
6.2	Methodology	206
6.2.1	Sample size calculation	206
6.2.2	Preparation of culture media	207
6.2.3	Fungal isolates.....	207
6.2.4	Inoculum preparation.....	207
6.2.5	Neubauer chamber cell counting.....	208
6.2.6	Plating method.....	208
6.2.7	Blood spiking preparation	209
6.2.7(a)	Fresh whole blood.....	209
6.2.7(b)	Blood culture bottle	209
6.2.8	Subculturing and Gram staining.....	210
6.2.9	Fungal DNA extraction from blood samples.....	211
6.2.10	Evaluation of the real-time PCR assay using spiked blood samples	211
6.3	Result.....	213
6.3.1	Performance of blood culture bottle	213
6.3.1(a)	Subculturing and Gram staining	213
6.3.1(b)	DNA extraction and evaluation on the developed multiplex real-time PCR.....	214
6.3.2	Performance of multiplex real-time PCR on spiked blood samples.....	215
6.3.3	Evaluation of the developed multiplex real-time PCR assay with the gold standard method	215
6.4	Discussion	220
CHAPTER SEVEN: GENERAL DISCUSSION.....		
		224
CHAPTER EIGHT: CONCLUSION, LIMITATIONS AND FUTURE RECOMMENDATIONS		
		232

REFERENCES..... 234

APPENDICES

LIST OF PUBLICATIONS

LIST OF TABLES

		Page
Table 2.1	Epidemiological cut-off values ($\mu\text{g/ml}$) set by CLSI and EUCAST for <i>A. fumigatus</i> and <i>A. flavus</i> . Adapted from (Rudramurthy et al., 2019).....	25
Table 2.2	Extracellular hydrolytic enzymes and their functions in <i>Candida</i> species. Adopted from (Mba & Nweze, 2020).....	36
Table 3.1	(a) Comparison of <i>A. fumigatus</i> DNA extraction methods from spiked blood based on duration, detection limit, method involved and sample volume.....	94
Table 3.1	(b) Comparison of <i>C. albicans</i> DNA extraction methods from spiked blood based on duration, detection limit, method involved and sample volume.....	95
Table 4.1	List of primer characteristics designed in this study.....	116
Table 4.2	List of probe characteristics designed in this study.....	118
Table 4.3	(a) Homo- and heterodimerizations between primers designed in this study.....	120
Table 4.3	(b) Homo- and heterodimerizations between primers and probes designed in this study.....	120
Table 4.3	(c) Homo- and heterodimerizations between probes designed in this study.....	120
Table 4.4	Amplicon sizes of the oligonucleotides used in this study.....	122
Table 5.1	Real-time PCR parameter condition.....	155
Table 5.2	List of organisms and their source used for the analytical specificity evaluation.....	159
Table 5.3	(a) Optimization of <i>bgt1</i> primer concentrations.....	172
Table 5.3	(b) Optimization of <i>benA</i> primer concentrations.....	172
Table 5.3	(c) Optimization of ITS2 primer concentrations.....	172
Table 5.3	(d) Optimization of <i>LEU2</i> primer concentrations.....	172
Table 5.4	(a) Optimization of <i>bgt1</i> probe concentrations.....	178
Table 5.4	(b) Optimization of <i>benA</i> probe concentrations.....	178
Table 5.4	(c) Optimization of ITS2 probe concentrations.....	178

Table 5.4	(d) Optimization of <i>LEU2</i> probe concentrations.....	178
Table 5.5	Performance of IAC monoplex real-time PCR assay.....	184
Table 5.6	Sensitivity of IAC DNA template in monoplex real-time PCR assay.....	184
Table 5.7	(a) Comparison of performance between monoplex and multiplex real-time PCR assays for detection of <i>A. fumigatus</i> ...	189
Table 5.7	(b) Comparison of performance between monoplex and multiplex real-time PCR assays for detection of <i>A. terreus</i>	190
Table 5.7	(c) Comparison of performance between monoplex and multiplex real-time PCR assays for detection of <i>C. albicans</i>	190
Table 5.7	(d) Comparison of performance between monoplex and multiplex real-time PCR assays for detection of <i>C. glabrata</i>	192
Table 5.8	Mean threshold value (Cq), standard deviation and coefficient of variation (CV) of multiplex real-time PCR assay for each targeted organism.....	193
Table 5.9	List of organisms tested for analytical specificity of the developed multiplex real-time PCR assay.....	195
Table 5.10	Intra-assay evaluation of the multiplex real-time PCR.....	196
Table 6.1	Sample size calculation for the evaluation of developed multiplex real-time PCR assay using Microsoft Excel Sample Size Calculator (Version 2.0).....	206
Table 6.2	Sensitivity evaluation on the developed multiplex real-time PCR assay from spiked blood samples.....	217
Table 6.3	Computational of spiked blood samples performance on the developed multiplex real-time PCR assay.....	219
Table 6.4	The performance of multiplex real-time PCR assay on spiked blood samples.....	219

LIST OF FIGURES

		Page
Figure 2.1	List of fungal pathogens prioritized by the World Health Organization (WHO).....	10
Figure 2.2	Infectious life cycle of <i>Aspergillus fumigatus</i>	12
Figure 2.3	Phylogenetic tree based on six genes consisted of 3395 base pairs by maximum likelihood method.....	17
Figure 2.4	Distribution of <i>Candida</i> species in 42 intensive care unit studies over 20 years.....	30
Figure 2.5	The regulation of biofilm development of <i>Candida</i> species...	35
Figure 2.6	Pathogenesis of invasive candidiasis.....	38
Figure 2.7	Structure and composition of <i>Aspergillus fumigatus</i> cell wall..	46
Figure 2.8	Structure and composition of <i>Candida albicans</i> cell wall.....	47
Figure 3.1	Cell counting system designed for accuracy and consistency.....	77
Figure 3.2	DNeasy Blood & Tissue Kit (QIAGEN Inc., Germany).....	79
Figure 3.3	Wizard® Genomic DNA Purification Kit (Promega Corporation, USA).....	81
Figure 3.4	NucleoSpin® Blood QuickPure (Machery-Nagel, Germany)..	82
Figure 3.5	Genomic DNA Mini Kit (GeneAid Biotech Ltd., Taiwan)....	83
Figure 3.6	Illustra Blood GenomicPrep Mini Spin Kit (GE Healthcare, UK).....	84
Figure 3.7	Kaneka Easy DNA Extraction Kit version 2 (Kaneka Corporation, Japan).....	85
Figure 3.8	Summary of flow methodology in Chapter 3.....	89
Figure 3.9	(a) Agarose gel electrophoresis showing amplicons of ITS PCR using template DNA produced by eight DNA extraction methods.....	92

Figure 3.9	(b) Agarose gel electrophoresis showing amplicons of ITS PCR using template DNA produced by eight DNA extraction methods.....	93
Figure 4.1	The primers and probes were designed using IDT DNA PrimerQuest online tool at IDT Homepage (https://sg.idtdna.com/PrimerQuest/Home/Index).....	103
Figure 4.2	The hairpin formation, homodimer and heterodimer analysis using IDT Oligo Analyzer tool version 3.1 (https://sg.idtdna.com/calc/analyzer).....	106
Figure 4.3	Summary of flow methodology in Chapter 4.....	112
Figure 4.4	A representative analysis of primer sets. The representative analyses of a primer pair targeting <i>A. terreus</i> reveal detailed primer reports.....	116
Figure 4.5	(a) Annealing locations of the primers and probe of <i>A. fumigatus</i>	125
Figure 4.5	(b) Specificity test of bgt1_F and bgt1_R primers on different fungi ($n=10$) by monoplex PCR.	126
Figure 4.5	(c) Specificity test of bgt1_P probe and bgt1_R primer on different fungi ($n=10$) by monoplex PCR.....	127
Figure 4.6	(a) Annealing locations of the primers and probe of <i>A. terreus</i>	129
Figure 4.6	(b) Specificity test of BenA_F and BenA_R primers on different fungi ($n=9$) by monoplex PCR.....	130
Figure 4.6	(c) Specificity test of BenA_P probe and BenA_R primer on different fungi ($n=9$) by monoplex PCR.....	131
Figure 4.7	(a) Annealing locations of the primers and probe of <i>C. albicans</i>	133
Figure 4.7	(b) Specificity test of ITS2_F and ITS2_R primers on different fungi ($n=9$) by monoplex PCR.....	134
Figure 4.7	(c) Specificity test of ITS2_P probe and ITS2_R primer on different fungi ($n=9$) by monoplex PCR.....	135
Figure 4.7	(d) Optimization of annealing temperature and primer concentration for <i>C. albicans</i> and <i>C. orthopsilosis</i>	136

Figure 4.8	(a) Annealing locations of the primers and probe of <i>C. glabrata</i>	138
Figure 4.8	(b) Specificity test of LEU2_F and LEU2_R primers on different fungi ($n=9$) by monoplex PCR.....	139
Figure 4.8	(c) Specificity test of LEU2_P probe and LEU2_R primer on different fungi ($n=9$) by monoplex PCR.....	140
Figure 4.9	Gel electrophoresis of multiplex PCR amplicons of <i>bgt1</i> gene, <i>benA</i> gene, ITS2 gene and <i>LEU2</i> gene from spiked blood samples.....	142
Figure 4.10	Gel electrophoresis of multiplex PCR amplicons of <i>bgt1</i> gene, <i>benA</i> gene, ITS2 gene and <i>LEU2</i> gene from culture samples...	144
Figure 5.1	Summary of flow methodology in Chapter 5.....	161
Figure 5.2	(a) Preliminary specificity analysis of <i>bgt1</i> gene on monoplex real-time PCR for <i>A. fumigatus</i>	166
Figure 5.2	(b) Preliminary specificity analysis of <i>benA</i> gene on monoplex real-time PCR for <i>A. terreus</i>	166
Figure 5.2	(c) Preliminary specificity analysis of ITS2 gene on monoplex real-time PCR for <i>C. albicans</i>	167
Figure 5.2	(d) Preliminary specificity analysis of <i>LEU2</i> gene on monoplex real-time PCR for <i>C. glabrata</i>	167
Figure 5.3	(a) The optimization of primer concentration of <i>bgt1</i> gene for <i>A. fumigatus</i>	170
Figure 5.3	(b) The optimization of primer concentration of <i>benA</i> gene for <i>A. terreus</i>	170
Figure 5.3	(c) The optimization of primer concentration of ITS2 gene for <i>C. albicans</i>	171
Figure 5.3	(d) The optimization of primer concentration of <i>LEU2</i> gene for <i>C. glabrata</i>	171
Figure 5.4	(a) The optimization of probe concentration of <i>bgt1</i> gene for <i>A. fumigatus</i>	176
Figure 5.4	(b) The optimization of probe concentration of <i>benA</i> gene for <i>A. terreus</i>	176

Figure 5.4	(c) The optimization of probe concentration of ITS2 gene for <i>C. albicans</i>	176
Figure 5.4	(d) The optimization of probe concentration of <i>LEU2</i> gene for <i>C. glabrata</i>	176
Figure 5.5	Amplification curve of preliminary specificity analysis of the <i>glmM</i> gene using monoplex real-time PCR for <i>H. pylori</i>	180
Figure 5.6	Amplification curve representing the optimization process for the primer concentration of the IAC.....	182
Figure 5.7	Amplification curve of optimization of IAC template concentration ranging from 2 pg to 2 ng.....	184
Figure 5.8	Amplification curves of multiplex real-time PCR.....	185
Figure 5.9	(a) The performance of multiplex real-time PCR for FAM (blue) and Cy5 channels (purple).....	186
Figure 5.9	(b) The performance of multiplex real-time PCR for Texas Red (red) and Cy5 channels (purple).....	186
Figure 5.9	(c) The performance of multiplex real-time PCR for HEX (orange) and Cy5 channels (purple).....	187
Figure 5.9	(d) The performance of multiplex real-time PCR for Cy5.5 (green) and Cy5 channels (purple).....	187
Figure 5.10	(a) Standard curve of the developed real-time PCR for the detection of <i>A. fumigatus</i> . Monoplex (orange square) versus multiplex (blue circle) assays.....	189
Figure 5.10	(b) Standard curve of the developed real-time PCR for the detection of <i>A. terreus</i> . Monoplex (orange square) versus multiplex (blue circle) assays.....	190
Figure 5.10	(c) Standard curve of the developed real-time PCR for the detection of <i>C. albicans</i> . Monoplex (orange square) versus multiplex (blue circle) assays.....	191
Figure 5.10	(d) Standard curve of the developed real-time PCR for the detection of <i>C. glabrata</i> . Monoplex (orange square) versus multiplex (blue circle) assays.....	192

Figure 5.11	Amplification curves representing 19 non-targeted organisms of the analytical specificity test on the developed multiplex assay.....	194
Figure 6.1	Summary of flow methodology in Chapter 6.....	212
Figure 6.2	Representative of microscope examination of <i>Candida glabrata</i> under X100 oil immersion objective.....	214

LIST OF SYMBOLS

+	Plus
-	Minus
×	Multiplication
÷	Division
±	Plus-minus
~	Approximately
%	Percentage
<	Less than
>	More than
≤	Less than or equal
≥	More than or equal
°C	Degree Celcius
α	Alpha
β	Beta
Δ	Delta
μ	Micro sign
™	Trademark sign
®	Registered sign

LIST OF ABBREVIATIONS

ΔG	Delta G
A_{260}/A_{230}	Absorbance at 260 nm per absorbance at 230 nm
A_{260}/A_{280}	Absorbance at 260 nm per absorbance at 230 nm
ABPA	Allergic bronchoalveolar aspergillosis
AIDS	Acquired immunodeficiency syndrome
ATCC	American Type Culture Collection
BAL	Bronchoalveolar lavage
BDG	1,3- β -D-glucan
BHI	Brain-Heart infusion medium
BLAST	Basic Local Alignment Search Tool
CDC	Centers for Disease Control
CF	Complement fixation
CFU	Colony-forming unit
CIE	Counter-immunoelectrophoresis
CLSI	Clinical & Laboratory Standard Institute
COPD	Chronic obstructive pulmonary disease
COVID-19	Coronavirus disease 2019
Cq	Cycle threshold
CSF	Cerebral spinal fluid
CT	Computed tomography
DNA	Deoxyribose nucleic acid
EAPRI	European Aspergillosis PCR Initiative
ECV	Epidemiology cut-off
EDTA	Ethylenediamine tetraacetic acid
ELISA	Enzyme-Linked ImmunoSorbent Assay
EUCAST	European Committee in Antimicrobial Susceptibility Testing
FDA	Food and Drug Administration
FFPE	Formalin-fixed paraffin-embedded
FISH	Fluorescence in situ hybridization
GM	Galactomannan
GMS	Gomori methenamine silver
HCl	Hydrochloric acid
HIV	Human immunodeficiency virus
HSCT	Hematopoietic stem cell transplantation
HUSM	Hospital Universiti Sains Malaysia

IA	Invasive aspergillosis
IAC	Internal amplification control
IC	Invasive candidiasis
ICU	Intensive care unit
IFI	Invasive fungal infection
IPA	Invasive pulmonary aspergillosis
ISHAM	International Society for Human and Animal Mycology
ITS	Internal transcribed spacer
IV	Intravenous
LOD	Limit of detection
MALDI-TOF MS	Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry
MIQE	Minimum Information for Publication of Quantitative Real-Time PCR Experiment
MSG	Mycoses Study Group
NCBI	National Center for Biotechnology Information
NGS	Next-generation sequencing
ODI	Optical Density Index
PAS	Periodic acid-Schiff
PCR	Polymerase chain reaction
PMN	Polymorphonuclear cell
PNA	Peptide nucleic acid
RFU	Relative fluorescence units
RIA	Radio-immunosorbent assay
RNA	Ribonucleic acid
ROI	Reactive oxygen intermediates
rRNA	ribosomal ribonucleic acid
SARS-CoV 2	Severe acute respiratory syndrome coronavirus 2
SDA	Sabouraud Dextrose Agar
SDS	Sodium dodecyl sulfate
Taq	Thermus aquaticus
Th	T-helper
UV	Ultraviolet
v/v	Volume per volume
WHO	World Health Organization
w/v	Weight per volume

LIST OF APPENDICES

Appendix A	Reagents and chemicals used in this study
Appendix B	Equipment used in this study
Appendix C	Consumables used in this study
Appendix D	Kits used in this study

PEMBANGUNAN UJIAN PCR MULTIPLEKS MASA NYATA BAGI PENGESANAN PATOGEN FUNGI DALAM MIKOSIS INVASIF

ABSTRAK

Mikosis invasif merupakan ancaman yang sangat mencabar kepada individu yang sistem imunnya terjejas dan sering kali menyebabkan keadaan morbiditi dan mortaliti yang teruk. Keberkesanan kaedah diagnostik semasa yang terbatas disebabkan oleh kelewatan dalam pengenalpastian jangkitan kulat yang turut mengakibatkan kelewatan dalam memulakan rawatan antikulat yang sesuai. Ini adalah berpunca daripada kelemahan kaedah konvensional. Kajian ini dijalankan untuk menyiasat mengenai protokol pengekstrakan DNA kulat dan pembangunan ujian tindak balas berantai polimerase (PCR) multipleks masa nyata untuk pengesanan patogen kulat invasif yang lebih cepat. Pembangunan ujian PCR multipleks masa nyata ini mampu mengenalpasti serentak pelbagai spesies kulat yang lazimnya dikaitkan dengan mikosis invasif secara serentak. Reka bentuk primer yang spesifik kepada spesies dan pengoptimuman asai menyasarkan *Aspergillus fumigatus*, *Aspergillus terreus*, *Candida albicans*, dan *Candida glabrata*. Keputusan kajian menunjukkan beberapa kaedah pengekstrakan DNA yang menghasilkan kepekaan dan kecekapan masa yang lebih unggul dengan implikasi besar bagi kegunaan klinikal. Ujian PCR multipleks masa nyata yang dibangunkan menunjukkan ketepatan yang tinggi dalam mengenal pasti patogen kulat. Sebanyak 65 isolat termasuk pelbagai strain kulat dan strain rujukan lain menunjukkan 100% spesifik bagi organisma sasaran untuk ujian spesifisiti analitik. Penilaian prestasi ujian PCR multipleks menggunakan sampel darah yang

diinokulasi dengan organisma (*spiked blood samples*) menunjukkan sensitiviti dan spesifisiti yang tinggi di mana kedua-duanya pada 100% dengan nilai ramalan positif (PPV) dan nilai ramalan negatif (NPV) juga pada 100%. Secara keseluruhan, penyelidikan ini menyumbang kepada peningkatan diagnosis makmal dan pengurusan jangkitan kulat yang invasif. Dengan menangani cabaran dalam pengekstrakan DNA kulat dan mencipta ujian PCR multipleks yang berkualiti tinggi, kajian ini menunjukkan pendekatan diagnosis yang lebih efisien dan meningkatkan penjagaan pesakit dan hasil rawatan. Kajian penilaian lanjutan menggunakan sampel klinikal yang sebenar disyorkan untuk memperkukuhkan lagi nilai aplikasi kaedah ini dalam situasi klinikal masa kini.

DEVELOPMENT OF A MULTIPLEX REAL-TIME PCR ASSAY FOR DETECTION OF FUNGAL PATHOGENS IN INVASIVE MYCOSES

ABSTRACT

Invasive mycoses pose significant challenges to immunocompromised individuals, often resulting in severe morbidity and mortality. Current diagnostic methods are hindered by delays in identification and initiation of appropriate antifungal therapy, stemming from the limitations of conventional techniques. This study undertakes a thorough investigation into fungal DNA extraction protocols and the development of a multiplex real-time PCR assay for rapid identification of invasive fungal pathogens. This research aims to compare fungal DNA extraction methods and develop a multiplex real-time PCR assay capable of simultaneously identifying multiple fungal species commonly associated with invasive mycoses. Species-specific primer design and assay optimization target *Aspergillus fumigatus*, *Aspergillus terreus*, *Candida albicans*, and *Candida glabrata*. Results reveal certain extraction methods exhibiting superior sensitivity and time efficiency, with implications for clinical use. The developed multiplex real-time PCR assay demonstrates promising accuracy in identifying fungal pathogens. Analytical specificity testing, which involved detecting 65 isolates including various fungal strains alongside other reference strains, yielded a 100% identification rate for target organisms. Performance evaluation of the multiplex PCR assay using spiked blood samples showed high specificity and sensitivity, both at 100%, with positive predictive value (PPV) and negative predictive value (NPV) also at 100%. Overall, this research contributes to advancing laboratory diagnosis and management of

invasive fungal infections. By addressing challenges in fungal DNA extraction and creating a high-performance multiplex PCR assay, this study lays the groundwork for more efficient and reliable diagnostic approaches, thereby enhancing patient care and treatment outcomes. Further validation studies on real clinical samples are recommended to confirm the applicability of these methodologies in the current clinical settings.

CHAPTER ONE

INTRODUCTION

1.1 Problem statement

Invasive mycoses represent a formidable threat to individuals with compromised immune systems, often leading to severe morbidity and mortality. The current diagnostic landscape is fraught with challenges, characterized by delayed identification and subsequent start of suitable antifungal treatment due to the limitations of conventional methods. This study seeks to address this critical gap by focusing on the development of a molecular diagnostic assay capable of simultaneously detecting various invasive fungal pathogens. The lack of a comprehensive and rapid diagnostic tool has profound clinical implications, resulting in delayed interventions and compromised patient outcomes.

The urgency of this study is underscored by the need to revolutionize diagnostic approaches, providing clinicians with a swift and accurate means of identifying invasive mycoses. The anticipated assay aims to improve the precision of diagnosis, enabling early therapeutic interventions tailored to the specific fungal pathogens involved. Furthermore, the study recognizes the potential economic impact of such a diagnostic advancement, as it could contribute to more cost-effective and efficient healthcare delivery by streamlining diagnostic processes and reducing unnecessary treatments. Through this investigation, the aim is to bridge the existing diagnostic gap, enhance patient care, and ultimately contribute to a substantial reduction in the burden posed by invasive mycoses on both healthcare systems and affected individuals.

1.2 Rationale of the study

Increased incidence of invasive mycoses has prompted various investigations which include finding ways to overcome diagnostics and management problems in the susceptible cohort of patients. Detection of invasive fungal infections have been a diagnostic dilemma for both clinicians and medical microbiology laboratory technologists which lies in the need for accurate and timely identification of these fungal infections. In immunocompromised patients, invasive mycoses like invasive aspergillosis and candidemia pose life-threatening risks. An early detection and appropriate treatment are crucial for improving the patient outcomes.

Current diagnostics depend on conventional culture methods with aid of serological tests and limited molecular diagnostic methods, which may be available in reference centres (Kidd et al., 2019; Mendonca et al., 2022). They have limitations in terms of sensitivity, specificity and turnaround time. Protocols for DNA extraction ranged from simple commercialized kit-based method (which may not give good yield) to laborious chloroform-based methods (which may not be feasible in a routine diagnostic laboratory). Nevertheless, the currently published protocols still did not provide the best result, optimum DNA extraction, particularly from clinical samples.

It is of paramount importance to accurately identify fungal pathogens such as *Aspergillus* and *Candida* species, as these are the most frequently encountered pathogens causing invasive fungal infections and specific treatment must be initiated promptly. In clinical setting, once a susceptible patient is suspected to have invasive aspergillosis, an effective pre-emptive therapy must be commenced

immediately. Unfortunately, the occurrence of *Aspergillus* species detection remains uncertain until results can be produced by the laboratory which may take up to one week (Cadena et al., 2016). Therefore, it would be very beneficial if it can be detected directly from the clinical specimen for example blood in timely manner.

As the currently available assays could not be standardized due to poor reliability, further studies need to be embarked to provide the solutions i.e. optimization of DNA extraction from clinical samples and timely detection of fungal pathogens in multiplex real-time PCR assay format. This assay could provide several benefits, including the ability to identify infections caused by different fungal pathogens in a single test, enabling prompt initiation of targeted antifungal therapy. This study is focused to develop a sensitive and specific multiplex real-time PCR for simultaneously detecting invasive *Aspergillus fumigatus*, *Aspergillus terreus*, *Candida albicans* and *Candida glabrata*.


1.3 Research questions of the study

1. What are the most effective DNA extraction methods for detecting fungal DNA in clinical samples using PCR assay?
2. How can specific primers be designed to specifically target invasive mycoses (*A. fumigatus*, *A. terreus*, *C. albicans* and *C. glabrata*)?
3. How can a multiplex real-time PCR assay be developed and optimized for the simultaneous detection of pathogen in invasive mycoses?
4. What are the key parameters to consider for the analytical validation of the developed multiplex real-time PCR assay?
5. How does the developed multiplex PCR assay perform in terms of sensitivity, specificity and accuracy when tested on clinical samples?

1.4 Objectives of the study

1. To optimize fungal DNA extraction methods for its effective detection in clinical samples by PCR assay.
2. To design specific primers targeting *Aspergillus fumigatus*, *Aspergillus terreus*, *Candida albicans*, and *Candida glabrata* (monoplex PCR).
3. To optimize and develop the multiplex real-time PCR for simultaneous detection of *Aspergillus* spp. and *Candida* spp. and an internal control gene.
4. To incorporate internal control gene detection in the multiplex real-time PCR assay developed in the third objective.
5. To perform analytical validation (sensitivity & specificity) of the developed multiplex real-time PCR assay.
6. To evaluate the performance of the developed multiplex real-time PCR assay in clinical samples and spiked samples.

1.5 Flow chart of the study



CHAPTER TWO

LITERATURE REVIEW

2.1 Invasive fungal infections

Invasive fungal infections (IFIs) account for 1.5 million death and up to three million people are infected annually worldwide (Fernandes, C. M. et al., 2022; Shaw, 2022; Zhang et al., 2022). These fungal infections are potentially life threatening in numerous types of patients, including solid organ transplantation, chemotherapy and extended duration in the intensive care unit (ICU) (Kim, D. Y. et al., 2022). In public health, IFIs are among the biggest concerns which lack of implementation of definitive diagnosis (Osman et al., 2020). These IFIs are the primary cause of death for immunocompromised hosts, with invasive aspergillosis being the primary cause of death in these individuals (Fidler et al., 2022).

Since coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hit the world at the end of 2019, IFIs represent with a significant increase in mortality, morbidity and length of hospital stay in severely ill patients at their middle and latter stages (Cattaneo et al., 2023). Besides, the World Health Organization (WHO) published in October 2022 an outline of the first list of priority fungal pathogens (Figure 2.1) that present the treat to public health (Fisher & Denning, 2023). The primary aim of is combatting the IFIs associated with these pathogens. The formal acknowledgment by the WHO spotlights a category of infections that have long been overlooked in terms of both awareness and the research funding required to effectively address the escalating impact of these diseases (Fisher & Denning, 2023).

Of utmost significance on this list were *Aspergillus fumigatus*, *Candida*

albicans, *Candida auris* and *Cryptococcus neoformans*, followed by *Candida glabrata*, *H. capsulatum*, and various fungi responsible for mucormycosis or mycetoma. *Fusarium* species and *Candida tropicalis* were classified as highly important. This comprehensive assessment generated a range of recommendations, emphasizing three key priority areas which are research and development, public health interventions, and surveillance (Fisher & Denning, 2023).

IFIs can be broadly categorized into two categories based on their characteristics and clinical significance. The first category consists endemic mycoses, which are caused by specific fungal pathogens and are typically associated with specific geographic regions. These endemic mycoses include blastomycosis, coccidioidomycosis, histoplasmosis, paracoccidioidomycosis, penicilliosis, and sporotrichosis (Osman et al., 2020). Each of these infections is caused by particular fungal species and is often found in specific areas around the world.

The second category encompasses opportunistic mycoses, which are caused by a diverse group of fungi and tend to affect individuals with underlying health conditions or compromised immune systems. These infections include invasive aspergillosis, invasive candidiasis, cryptococcosis, hyalohyphomycosis, phaeohyphomycosis and zygomycosis (Osman et al., 2020), can be pose significant challenges in healthcare settings. These infections are frequently linked to individuals with weakened immune systems, such as cancer patients, individuals with HIV, organ transplant recipients, and individuals on immunosuppressive therapies. It is imperative to grasp the attributes and risk factors of opportunistic mycoses to effectively control and prevent these infections among susceptible populations.

In accordance with the WHO's recommendations, strategies aimed at reducing the worldwide impact of fungal diseases which include enhanced surveillance of fungal infections, ensuring cost-effective availability of diagnostic tools near patients. Moreover, there is a demand for focused support for research and development to expedite the deployment of novel antifungal medications and improved diagnostic methods (Fisher & Denning, 2023).




Figure 2.1 List of fungal pathogens prioritized by the World Health Organization (WHO). Adopted from (CDC, 2022).

2.2 Invasive aspergillosis

Invasive aspergillosis (IA) is an opportunistic, potentially fatal and systemic infectious disease causes of mortality and morbidity which is usually encountered in immunocompromised patients (Badiee et al., 2022; Lian et al., 2022). IA is severe form of IFIs in immunocompromised hosts caused by *Aspergillus* species (Sato et al., 2022) and mainly found in the respiratory tract system and it spreads from pulmonary locations to the brain, skin, kidney, liver, and gut (Badiee et al., 2022). Besides, the prevalence is on the rise among non-neutropenic patients with significant underlying conditions, including patients in ICU, patients who undergone solid organ transplantation, patients with viral infections caused by SARS-CoV-2, patients with chronic obstructive pulmonary disorder (COPD) and other respiratory complications (Jenks et al., 2021).

A. fumigatus has an extensive environmental presence that is part of its infectious life cycle. It produces conidia that are airborne by asexual reproduction (Figure 2.2). When inhaled by specific patient groups with weakened immune systems, these conidia establish themselves in the lungs. Subsequently, they undergo germination, leading to two possible outcomes: either controlled fungal growth with pronounced inflammation mediated with corticosteroid therapy, or uncontrolled hyphal growth without polymorphonuclear cell (PMN) infiltration especially in cases of corticosteroid therapy. In severe instances, this uncontrolled growth can result in dissemination, particularly in cases of neutropenia (Dagenais & Keller, 2009).




Figure 2.2 Infectious life cycle of *Aspergillus fumigatus*.

2.2.1 Burden of disease and epidemiology

Due to changes in epidemiological patterns, numerous emerging fungi are becoming increasingly significant in causing infections among immunocompromised individuals. Recent published data provides evidence that the incidence of invasive aspergillosis (IA) is on the rise in several countries, including France and a significant number of cases go undetected and are only diagnosed during autopsy (Danion et al., 2019).

After candidemia and *Pneumocystis pneumonia*, IA is the third most common cause of fungal infection disease in France. In a number of countries, including France, the incidence of IA has been rising. From 1.1 cases per 100,000 people in 2001 to 1.8 cases per 100,000 people in 2010, this incidence increased by +4.4% annually. Recent data indicates that a significant number of cases go undetected and are only diagnosed post-mortem (Danion et al., 2019). A published study based on autopsies conducted in Japan from 1989 to 2009 revealed that the fungal infections were found in 4.5% of the 13,787 cases with (49%) 299 cases involving *Aspergillus* species (Suzuki et al., 2017). While the percentage of cases of severe aspergillosis has declined since 2001, *Aspergillus* species infections have become more common over time (Danion et al., 2019).

Besides, a multicentric study by Chakrabarti et al. found that *Aspergillus* species were the most frequently isolated fungi in patients with non-classical risk factors. The study, which examined invasive mold infections in Indian intensive care units with a total of 142 cases of IA were found (63.5%) (Chakrabarti et al., 2019; Rudramurthy et al., 2019). Furthermore, more recent observations indicate that IA can occur simultaneously with severe even in individuals who appear to have a normal immune response (Rudramurthy et al., 2019).

Aspergillus species were responsible for most invasive mold infections. *A. fumigatus* stood out as the most frequently isolated species, although in India, *A. flavus* was equally prevalent. This observation aligns with prior findings (Slavin & Chakrabarti, 2012) and may be linked to the hot climate conditions (Rotjanapan et al., 2018). In fact, an aerobiological survey carried out in Delhi revealed that *A. flavus* was the most commonly occurring *Aspergillus* (Rotjanapan et al., 2018).

However, the impact of climate is less straightforward, as shown by the persistence of *A. fumigatus* as the predominant mold in Singapore and Thailand, two countries with consistently hot climates, like those found in temperate regions. Interestingly, under temperatures between 20 to 30°C, the germination rates of various *Aspergillus* species were found to be similar. Yet, the germination rate of *A. fumigatus* rose to 41°C, while that of *A. flavus* decreased by 45% (Araujo & Rodrigues, 2004; Rotjanapan et al., 2018). This phenomenon can be attributed to the fact that the mold concentrations in the air were lowest during the dry and hot summer months, rising during periods of precipitation (Park et al., 2010).

The epidemiology of IA is an intricate and evolving field, with data that can differ among regions and evolve over time. Hence, it is advisable to refer to local surveillance data for precise insights into IA within a particular population or setting. This approach can lead to more effective measures for mitigating the impact and burden of fungal infections.

2.2.2 Mycology and taxonomy

Over 250 distinct species of *Aspergillus* are arranged into numerous subgenera and sections that were once referred to as groupings. *A. fumigatus* is the most commonly found species in cases of invasive disease, followed by, followed by *A. flavus*, *A. terreus*, and *A. niger* (Arastehfar et al., 2021). Other species have also been associated with infections in severely immunocompromised patients. While it is generally not challenging to identify these fungi at the genus level, difficulties may arise, especially with poorly sporulating isolates, making identification even at the species complex level a daunting task (Cadena et al., 2016).

While certain species of *Aspergillus* may have a sexual form, most species reproduce asexually. The standard procedure is to refer to all fungi under one name, "Aspergillus," even if it is possible for both anamorph and teleomorph stages to occur. An Italian priest compared *Aspergillus* to the holy water sprinkler, or "aspergillum," based on the physical characteristics of the conidial head of the fungus (Rudramurthy et al., 2019). Researchers have uncovered cryptic *Aspergillus* species that share morphological characteristics with the primary *Aspergillus* sections. However, it has been discovered that a large number of these cryptic species have greater triazole minimum inhibitory concentrations (MICs) (Cadena et al., 2016).

In order to determine the relationships within the genus *Aspergillus* at the subgeneric level, identification of these organisms depends on molecular techniques, such as sequencing of particular genes like the internal transcribed spacer region, actin, beta-tubulin, RNA polymerase II, and calmodulin genes (Cadena et al., 2016; Sun et al., 2022). The recognition of cryptic species commenced with *A. lentulus*, which was identified as a subset of *A. fumigatus* characterized by poor sporulation and elevated triazole MICs. Subsequently, *Neosartorya pseudofischeri* was identified, followed by

the discovery of *A. udagawae*, *A. viridinutans*, *A. fumigatiaffinis*, and *A. novofumigatus* within the Fumigati section. Other examples of cryptic aspergillosis encompass *A. alliaceous* (Flavi section), *A. carneau*, and *A. alabamensis* (Terrei section); *A. tubingensis*, *A. awamori*, and *A. acidus* (Nigri section); and *A. calidoustus*, *A. insuetus*, and *A. kevei* (Usti section), among others (Cadena et al., 2016).

Phylogenetic method has played a role in addressing challenges pertaining to taxonomy and naming conventions (Figure 2.3) (Kocsube et al., 2016). Nonetheless, investigations employing multigene phylogenetic methods have revealed that *Aspergillus* forms a broadly monophyletic group, distinct from its closely related genus *Penicillium* (Kidd et al., 2023; Kocsube et al., 2016). This monophyletic nature of *Aspergillus* facilitated the retention of its name for the majority of species within the genus, ensuring the preservation of its clinical significance. Species traditionally recognized by their teleomorphs were consequently reclassified under the *Aspergillus* genus (Kidd et al., 2023).

Inter-laboratory variances have been raised by the difficulties in definitively identifying these organisms due to the lack of uniform identification protocols. There is ongoing discussion over the need of precise identification in treatment options and patient outcomes. This is because the majority of clinical trial participants are typically diagnosed with probable disease based on clinical symptoms, radiographic findings, specific blood tests, or bronchoalveolar lavage (BAL) results, such as the detection of galactomannan (GM), without the recovery of a definitive isolate. This is due to most clinical trials have not studied isolates to this level of detail (Johnson et al., 2012; Kidd et al., 2019).




Figure 2.3 Phylogenetic tree based on six genes consisted of 3395 base pairs by maximum likelihood method. Adopted from (Kocsube et al., 2016).

2.2.3 Virulence factors

In invasive aspergillosis (IA), various virulence factors play a role, including biofilm, haemolysin, α -amylase, lipase, proteinase, pectinase, and phospholipase. The formation of biofilm actively prevents the phagocytosis of *Aspergillus* species and allows exponential growth (Raksha et al., 2017). For example, haemolysin is produced by *A. fumigatus* isolates from diverse sources, including clinical and environmental samples. Its toxicity may stem from the ability of the haemolysin to induce DNA damage and mutations in animal models and cell cultures (Zarrin et al., 2017). These toxins can contribute to the pathogenesis *A. fumigatus* by directly invading host tissues. Various haemolysin can induce genotoxicity of dietary carcinogens *in vitro*, with the level of induction strongly dependent on the species (Zarrin et al., 2017). Additionally, haemolysin is responsible for the lysis of red blood cells (Raksha et al., 2017).

Enzyme production is a contributing factor in the virulence process. The positivity observed in environmental samples is lower than in patient samples. Virulence factors appears to be naturally present in environmental samples and persist in a small percentage to ensure survival in that environment (Ali et al., 2019). However, upon entry into the human tissue, their activity intensifies as a response to unfavourable conditions and the defensive mechanisms of the human body, which attempt to eliminate microorganisms (Ali et al., 2019).

Virulence factors of IA can confirm the pathogenicity and invasive nature of fungi. Detecting these factors not only aids in distinguishing pathogenic from non-pathogenic *Aspergillus* species but also assists physicians in initiating antifungal treatment when necessary (Raksha et al., 2017).

2.2.4 Risk factors

In immunocompromised patients, invasive aspergillosis (IA) constitutes a significant source of morbidity and mortality, with persistently high fatality rates despite advancements in antifungal treatment. Consequently, there is considerable interest in developing preventive measures and identifying key risk factors to guide prevention strategies (Baddley, 2011).

The risk factors for IA encompass various aspects, including the underlying health condition of the host, comorbidities, medications, and environmental factors. Extensive research has delved into these risk factors in specific populations, such as those with hematologic malignancies and transplant recipients. Additionally, emerging groups, including intensive care unit (ICU) patients, individuals with chronic obstructive pulmonary disease (COPD), HIV patients, and solid organ transplant recipients, have been studied (Baddley, 2011). Notably, the latest widespread occurrence of IA is observed in SARS-CoV-2 patients, characterized by immune dysregulation affecting both Th1 and Th2 responses (Montrucchio et al., 2021).

For COVID-19 patients, host-related comorbidities like COPD and asthma in the ICU are identified as risk factors for IA. Intriguingly, the data concerning the time elapsed between diagnosis presents notable considerations (Montrucchio et al., 2021). Significant variations in diagnostic latency may arise from the implementation of diverse screening strategies, such as GM testing, and the use of invasive BAL in intubated patients (Montrucchio et al., 2021).

2.2.5 Pathogenesis

Aspergillus species are widespread in nature, commonly found in natural environments like soil and decaying vegetation where they thrive as saprophytes, prolifically sporulating and dispersing conidia into the environment (Challa, 2018; Pathakumari et al., 2020). However, the risk of exposure to these conidia varies significantly, contingent upon climatic factors such as humidity, temperature and wind patterns (Challa, 2018). Generally, a healthy individual with intact host defence mechanisms rarely succumbs to disease after inhaling *Aspergillus* spp. conidia.

On the other hand, infections caused by *Aspergillus* species may lead to invasive infections in individuals with weakened immune systems, resulting in increased rates of morbidity and mortality (Challa, 2018). In high-risk populations such as individuals with HIV, neutropenia, cancer chemotherapy and bone marrow transplants, the mortality rate for IA can range from 40 to 90% (Pathakumari et al., 2020). Normally, the human host does not mount a response to *Aspergillus* spp. conidia even when exposed. This is due in part to the presence of abundant antimicrobial factors within the mucus layer of the sinopulmonary tract, which neutralize the conidia, and the ciliated epithelium, which actively clears them (Challa, 2018). Disease risk arises when the spore concentration remains consistently high, often exacerbated by hot and humid conditions, thus posing a threat to the host (Challa, 2018).

In such cases, the host initiates a robust inflammatory response, involving the recruitment of neutrophils and macrophages to eliminate the conidia (Challa, 2018). However, this response is carefully modulated and downregulated to prevent excessive tissue damage (Challa, 2018). Moreover, the mucus layer creates a nutrient-limited environment that inhibits conidia germination. Therefore, the intact ciliated epithelium, coupled with the mucus layer and the presence of neutrophils and alveolar

macrophages, holds an essential part to the host's defense systems. (Challa, 2018).

Aspergillus species employ various strategies to elude the immune system, such as concealing crucial pathogen-associated molecular patterns, inhibiting the fusion of phagosomes with lysosomes, and producing antioxidants like catalase and mannitol (Pathakumari et al., 2020). Furthermore, certain *Aspergillus* species produce specific secondary metabolites with various immunosuppressive effects, such as fumagillin, actibind, gliotoxin, and cytochalasin E (Pathakumari et al., 2020). The capacity of *Aspergillus* to produce melanin pigment, serving various purposes such as shielding conidia from adverse external conditions outside their mammalian hosts and scavenging reactive oxygen intermediates (ROI) within host cells, is another distinguishing characteristic that sets them apart from other fungi (Pathakumari et al., 2020). Melanin also plays a role in interfering with the intracellular trafficking of phagocytosed conidia and masking β -glucans (Dagenais & Keller, 2009; Pathakumari et al., 2020).

Nonetheless, disease can still occur in specific scenarios, such as when the immune response is weakened, as seen in IA, or when it becomes overly exuberant, as observed in conditions like allergic fungal rhinosinusitis (AFRS) or allergic bronchoalveolar aspergillosis (ABPA) (Challa, 2018). Additionally, *Aspergillus* colonization and the formation of mycetomas may result from chronic inflammation or the presence of cavity lesions (Challa, 2018).

2.2.6 Clinical manifestations

The clinical manifestation of aspergillosis varies widely, contingent upon both the specific site of infection and the host's capacity to mount an effective and coordinated immune response. The upper respiratory tract, including the trachea,

bronchi, lung tissue, and adjacent structures, is commonly affected, although dissemination or infection can potentially affect any organ system (Cadena et al., 2016). The clinical syndromes associated with aspergillosis can be categorized into allergic presentations, non-invasive saprophytic infections, semi-invasive conditions, and invasive diseases (Cadena et al., 2016).

For non-invasive infections, there are two diseases: (1) aspergilloma and (2) allergic bronchopulmonary aspergillosis (ABPA). As aspergilloma, also known as an *Aspergillus* fungus ball, develops within an existing pulmonary cavity that is typically the result of conditions like emphysema, malignancy, or pulmonary tuberculosis. When observed on medical imaging, it appears as a solid mass that can move freely within the cavity. Clinical symptoms associated with aspergilloma vary, ranging from asymptomatic cases with radiographic findings discovered incidentally to severe cases with life-threatening haemoptysis necessitating immediate intervention (Denning, 2003). For individuals with symptomatic aspergilloma, surgical resection is a viable treatment option. However, surgical intervention is not feasible for several patients due to the presence of underlying structural lung disease and poor pulmonary function. In such cases, effective illness stabilization and management require a combination of embolization and antifungal medication (Cadena et al., 2016; Denning, 2003).

ABPA is a clinical condition characterized by ongoing immunological activation, lung infiltrates, and asthma (Shah & Panjabi, 2016), which may eventually lead to the development of bronchiectasis. Diagnostic criteria include various characteristics, such as the co-occurrence of eosinophilia, central bronchiectasis, pulmonary infiltrates, acute skin response to *A. fumigatus*, elevated serum immunoglobulin E levels, and the presence of anti-IgG precipitins against *Aspergillus*. It is important to note that none of these findings alone constitutes a definitive

diagnosis for this condition (Cadena et al., 2016; Greenberger et al., 2014). While radiological patterns may vary, a high-resolution computed tomography (CT) scan of the chest can often reveal the characteristic central bronchiectasis associated with the condition. Cavities and fibrosis are frequently observed in later stages of the illness (Greenberger et al., 2014). Following diagnosis, many patients are initiated on a combination of corticosteroids and itraconazole to expedite symptom improvement. However, previous research has demonstrated itraconazole's ability to reduce the need for corticosteroids during ABPA treatment. As such, attempts to gradually decrease or discontinue corticosteroid treatment ought to be done after the initial improvement. Patients who do not react to medication or who become intolerant to itraconazole can sometimes find success with other triazoles, such as posaconazole or voriconazole. However, there is a lack of information regarding the use of additional azoles and other medicines, such as omalizumab. (Cadena et al., 2016; Greenberger et al., 2014).

As for invasive diseases, invasive pulmonary aspergillosis (IPA) is one of them. IPA progresses relatively quick, typically within days to a few weeks, and has a high mortality rate, often exceeding 50% (Kanj et al., 2018). In most cases, patients were observed to exhibit symptoms within 10 to 21 days after hematopoietic stem cell transplantation (HSCT), particularly in the context of severe granulocytopenia. The most common clinical signs of IPA are haemoptysis, shortness of breath, fever, chest discomfort, or pleuritic pain. However, because they are unable to properly develop an inflammatory response, people with weakened immune systems, such as those suffering from neutropenia, may exhibit more subdued symptoms (Cadena et al., 2016). Fever may not be present in this patient group, and other symptoms, such as haemoptysis and pleuritic chest pain, which are frequently caused by angioinvasion, may be more noticeable (Cadena et al., 2016). A characteristic radiological finding

linked to IPA is the halo sign, which is a region of reduced attenuation encircling a pulmonary nodule. Nevertheless, imaging findings in high-risk patients usually lack specificity and closely resemble those of other pulmonary infections. Initial CT scan results followed by a progressive increase in lesion volume within the initial 7 days (Cadena et al., 2016; Caillot et al., 2001).

To confirm the diagnosis, histopathological features specific to *Aspergillus* are valuable. However, obtaining tissue for analysis can often be challenging due to underlying host characteristics such as thrombocytopenia or hemodynamic instability that preclude invasive diagnostic testing. Angioinvasion is a common hallmark of the condition when tissue samples are available. One morphological feature that may suggest the presence of invasive pulmonary aspergillosis (IPA) is the presence of dichotomous branching hyphae (Challa, 2018). However, these physical characteristics are not unique to *Aspergillus*, and a definitive diagnosis requires culture confirmation (Cadena et al., 2016).

The second one is tracheobronchitis. The significance of *Aspergillus* species in respiratory cultures can vary widely, encompassing colonization through to infection. Tracheobronchitis is characterized by an infection that is predominantly confined to the tracheobronchial tree (Cadena et al., 2016; Kanj et al., 2018). Clinical features of tracheobronchitis consist of non-specific symptoms, including cough, chest pain, fever, and haemoptysis, which can contribute to diagnostic delays. Bronchoscopy often reveals pseudo-membranes and ulcerative lesions. Since sputum cultures have limited sensitivity and specificity, additional diagnostic methods are often necessary for an accurate diagnosis. Dehiscence may occur in lung transplant recipients if tracheobronchitis affects the anastomotic site (Cadena et al., 2016). The management and treatment will be further explained in the next point.